Boehringer Ingelheim has partnered with Gubra, a specialized biotech company and preclinical CRO that specializes in peptide-based drug discovery for metabolic diseases, to launch phase 1 clinical trials for BI 3034701
This dual action helps in controlling blood sugar and improving insulin response, crucial for diabetes regulation
Is Semaglutide Just a Short-Term Fix
The universal conversion formula One formula handles every concentration, every dose, every syringe
Healthy mitochondria in a healthy human body produce the glutathione levels you need to thrive
This article was financially supported by National Institutes of Health Public Health Service grants R01 HL144790, R01 HL151493, R01 AI145813, R01 AI169687, R01 HL151769, and R01 HL159804 (OA)